Detection of serum anti-Helicobacter pylori immunoglobulin G in patients with different digestive malignant tumors.

AIM: To investigate the seroprevalence of Helicobacter pylori infection in patients with different digestive malignant tumors. METHODS: Enzyme linked. immunosorbent assay (ELISA) was used to detect serum anti-Helicobacter pylori IgG antibody in 374 patients with different digestive malignant tumors and 310 healthy subjects (normal control group). RESULTS: The seroprevalence of Helicobacter pylori infection was 61.50 %(230/374) and 46.77 % (145/310), respectively, in patients with digestive tumors and normal controls (P<0.05). The seroprevalence was 52.38 % (33/63), 86.60 % (84/97), 83.14 % (84/101), 45.24 (19/42), 51.13 % (18/35) and 44.44 % (16/36), respectively in patients with carcinomas of esophagus, stomach, duodenum, rectum, colon and liver (P<0.01). In patients with intestinal and diffuse type gastric cancers, the seroprevalence was 93.75 % (60/64) and 72.73 % (24/33), respectively (P<0.05). In patients with gastric antral and cardiac cancers, the seroprevalence was 96.43 % (54/56) and 73.17 % (30/41), respectively (P<0.05). In patients with ulcerous and proliferous type duodenal cancers, the seroprevalence of H pylori infection was 91.04 % (61/67) and 52.27 % (23/44), respectively (P<0.05). In patients with duodenal bulb and descending cancers, the seroprevalence was 94.20 % (65/69) and 45.20 % (19/42), respectively (P<0.05). CONCLUSION: H pylori infection is associated with occurrence and development of gastric and duodenal carcinomas. Furthermore, it is also associated with histological type and locations of gastric and duodenal carcinomas.